Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus.
In vivo transfection by intramuscular injection with plasmids expressing the immunogenic proteins of microbial pathogens has considerable potential as a vaccination strategy against many pathogens of both man and animals. Here we report that weanling mice given a single intramuscular injection of 50 micrograms of a plasmid, pSLE1 expressing the St. Louis encephalitis virus (SLE) prM/E protein under the control of the cytomegalovirus immediate early protein promoter produced SLE-specific antibody and were protected against lethal challenge with the virulent virus. Polynucleotide vaccine technology provides a unique opportunity to produce vaccines against flavivirus diseases of low incidence cheaply and rapidly, and to produce multivalent vaccines such as would be required for immunisation against dengue virus disease.
Phillpotts
R J
RJ
Microbiology Group, Chemical and Biological Defence Establishment, Porton Down, Wiltshire, U.K.
Venugopal
K
K
Brooks
T
T
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D002522:Chlorocebus aethiops; D004279:DNA, Viral / Q000276:immunology*; D004665:Encephalitis Virus, St. Louis / Q000276:immunology*; D004674:Encephalitis, St. Louis / Q000517:prevention & control*; D006801:Humans; D007114:Immunization; D051379:Mice; D011119:Polynucleotides / Q000276:immunology; D011817:Rabbits; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000235:genetics*; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D004279:DNA, Viral; D011119:Polynucleotides; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C074932:prM protein, Flavivirus; C065696:glycoprotein E, Flavivirus